Medical Condition News

RSS

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

Amgen today announced results from a small, randomized, placebo-controlled Phase 2 study indicating that adding AMG 479 to gemcitabine improved overall survival at six months (primary endpoint) and progression-free survival in patients with metastatic pancreatic cancer. The study, which also included a separate arm of conatumumab plus gemcitabine, is being presented in a Poster Discussion at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2010

Nasendoscopies help predict response to OAT in sleep apnea patients

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, nasendoscopy may help dentists predict oral appliance therapy success in sleep apnea patients. Nasendoscopy involves a flexible endoscope being inserted through the nasal cavity. The tip of the scope is placed at the level of the velopharynx and oro-/hypopharynx.

5 Jun 2010

Unsatisfactory interactions with physicians affect sickle cell disease patients' trust in medical profession

Faculty at the Johns Hopkins Berman Institute of Bioethics have published a study that shows, among adults with sickle cell disease, that unsatisfactory interactions with health-care providers in the past affect their trust in the medical profession more broadly.

5 Jun 2010

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Teva Pharmaceutical Industries Ltd. today announced positive results from a study assessing a new lower-volume injection of Copaxone® (glatiramer acetate) containing the currently approved dose in half the injection volume.

5 Jun 2010

Water is essential but electrolyte drinks are needed when exercising in heat

Water is essential when exercising in the heat but it might not be enough to keep you healthy in Houston summers.

5 Jun 2010

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

A recent retrospective study by four Michigan physicians shows strong evidence that symptoms of headache, dizziness and anxiety in some patients with traumatic brain injury potentially could be alleviated or even eliminated with specialized eyeglass lenses containing prisms.

5 Jun 2010

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Center.

5 Jun 2010

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings that will be presented at the American Society of Clinical Oncology annual meeting taking place June 4 - 8, 2010 in Chicago. Research highlights include a comparison of first-line treatments for an aggressive form of lymphoma, the efficacy and safety of a new genetically engineered cancer therapy, and the value of a commonly used tool for staging lymphoma.

5 Jun 2010

Acute neurological toxicity associated with chronic neurological toxicity in patients with high-grade gliomas

Patients with high-grade gliomas who experience acute (early) neurological toxicity during their treatment were more likely to experience chronic (late) neurological toxicity and shortened overall survival, according to researchers from the Kimmel Cancer Center at Jefferson. The study will be presented at the 2010 ASCO Annual Meeting in Chicago (Abstract #2037).

5 Jun 2010

Green tea component reduces leukemia cells in patients with CLL

An extract of green tea appears to have clinical activity with low toxicity in chronic lymphocytic leukemia (CLL) patients who used it in a phase II clinical trial, say researchers at Mayo Clinic.

5 Jun 2010

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2010

Encore Path signs license agreement for UMB technology that helps stroke patients redevelop natural gait

The University of Maryland, Baltimore's Office of Research and Development announced that Encore Path, Inc. of Baltimore signed an exclusive worldwide license agreement for a device technology invented jointly by researchers at the University of Maryland, Baltimore and the University of Maryland Baltimore County that helps stroke patients retrain their bodies to walk.

5 Jun 2010

HHF to open Terni Human Health Bioscience Institute

The Human Health Foundation, a nonprofit organization founded in 2006 to develop and fund biomedical research in Italy, will open the Terni Human Health Bioscience Institute for the investigation of breast, brain and lung cancer on June 7th in Terni, Italy.

5 Jun 2010

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Pacific Edge (PEB), a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately.

5 Jun 2010

VA partners with National Institutes of Health to research on Parkinson's disease

Veterans and others with Parkinson's disease who undergo deep brain stimulation may benefit from research co-sponsored by the Department of Veterans Affairs and published recently in the prestigious New England Journal of Medicine.

5 Jun 2010

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Sucampo Pharmaceuticals, Inc. today confirmed that its partner, R-Tech Ueno, Ltd. reported the results of its recently completed phase 2 clinical trial of UF-021 in retinitis pigmentosa patients. The results showed improvement in visual function dose-dependently in both visual field test and subjective findings.

5 Jun 2010

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Celgene International Sàrl today announced researchers at the annual meeting of the American Society of Clinical Oncology presented data from an evaluation of lenalidomide (REVLIMID) in patients with diffuse large B-cell lymphoma either with a germinal center B-cell or non-germinal center B-cell phenotype.

5 Jun 2010

Walter Reed Army Medical Center to treat pain patients with CTT's Calmare Pain Therapy Treatment

Competitive Technologies, Inc. announced today that the Walter Reed Army Medical Center in Washington, D.C., has joined the growing list of organizations that will treat pain patients with CTT's Calmare Pain Therapy Treatment, as authorized by the Surgeon General of the U.S. Army and Commanding General of the U.S. Army Medical Command.

5 Jun 2010

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Biomet, a global leader in the manufacture of orthopedic and biotechnology products, announced today that its subsidiary, Biomet Biologics, has enrolled the first subject into its multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial for critical limb ischemia (CLI).

5 Jun 2010

Ascenta Therapeutics, sanofi-aventis sign global licensing agreement for cancer drug candidates

Ascenta Therapeutics announced today the signing of a global collaboration and licensing agreement with sanofi-aventis covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death). These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor function and potentially enhancing cancer control and treatment.

4 Jun 2010

Medical Condition News

Amgen to present Phase 2 study data of AMG 479 in metastatic pancreatic cancer at 2010 ASCO

Nasendoscopies help predict response to OAT in sleep apnea patients

Unsatisfactory interactions with physicians affect sickle cell disease patients' trust in medical profession

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Water is essential but electrolyte drinks are needed when exercising in heat

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

Acute neurological toxicity associated with chronic neurological toxicity in patients with high-grade gliomas

Green tea component reduces leukemia cells in patients with CLL

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Encore Path signs license agreement for UMB technology that helps stroke patients redevelop natural gait

HHF to open Terni Human Health Bioscience Institute

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

VA partners with National Institutes of Health to research on Parkinson's disease

RTU announces phase 2 clinical trial results of UF-021 in patients with retinitis pigmentosa

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Walter Reed Army Medical Center to treat pain patients with CTT's Calmare Pain Therapy Treatment

Biomet Biologics initiates enrollment in MarrowStim P.A.D. Kit IDE trial for critical limb ischemia

Ascenta Therapeutics, sanofi-aventis sign global licensing agreement for cancer drug candidates

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Latest News